Duchenne Muscular Dystrophy (DMD)
Overview
Plain-Language Overview
Duchenne Muscular Dystrophy (DMD) is a genetic disorder that primarily affects the muscles responsible for movement. It causes progressive muscle weakness and loss of muscle mass, usually starting in early childhood. The condition mainly impacts the skeletal muscles, which control voluntary movements, and later affects the heart and breathing muscles. Children with DMD often have difficulty walking, climbing stairs, and may develop a waddling gait. Over time, the muscle weakness worsens, leading to loss of the ability to walk and complications with breathing and heart function. This disease is caused by a problem in a gene that helps produce a protein essential for muscle strength and stability.
Clinical Definition
Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder characterized by mutations in the DMD gene, leading to absence or severe deficiency of the dystrophin protein. Dystrophin is critical for maintaining the structural integrity of muscle cell membranes during contraction. The lack of dystrophin results in progressive muscle fiber degeneration and replacement by fat and fibrotic tissue. Clinically, DMD presents in early childhood with proximal muscle weakness, delayed motor milestones, and calf pseudohypertrophy. The disease progresses rapidly, causing loss of ambulation by early adolescence and eventual involvement of cardiac and respiratory muscles, leading to life-threatening complications. Elevated serum creatine kinase (CK) levels reflect ongoing muscle damage and are a hallmark laboratory finding.
Inciting Event
No external trigger; disease onset is due to inherited mutations in the DMD gene.
Muscle damage begins with the first muscle contractions in early childhood due to absent dystrophin.
Latency Period
Symptoms usually appear by 2 to 5 years of age after birth with normal early development.
Progressive muscle weakness develops over several years before diagnosis.
Diagnostic Delay
Early symptoms like delayed motor milestones and frequent falls are often attributed to developmental delay.
Mild initial weakness may be mistaken for benign clumsiness or other neuromuscular disorders.
Lack of awareness of family history or absence of obvious symptoms in female carriers delays suspicion.
Limited access to genetic testing or muscle biopsy in some settings prolongs diagnosis.
Clinical Presentation
Signs & Symptoms
Progressive proximal muscle weakness beginning in early childhood
Delayed motor milestones such as late walking
Frequent falls and difficulty climbing stairs
Respiratory difficulties in advanced disease
Cardiomyopathy symptoms including fatigue and arrhythmias
History of Present Illness
Progressive proximal muscle weakness beginning in the pelvic girdle and lower limbs.
Frequent falls, difficulty running, climbing stairs, and rising from the floor (positive Gowers' sign).
Enlarged calf muscles (pseudohypertrophy) due to fat and connective tissue replacement.
Delayed motor milestones such as walking after 18 months.
Later development of cardiomyopathy and respiratory muscle weakness.
Past Medical History
History of delayed motor development or early muscle weakness.
Elevated serum creatine kinase (CK) levels noted incidentally or during illness.
No prior neuromuscular diseases or trauma explaining symptoms.
Family History
Affected male relatives with similar progressive muscle weakness or known DMD diagnosis.
Carrier female relatives with elevated CK or mild muscle symptoms.
X-linked recessive pattern with maternal transmission of DMD mutations.
Physical Exam Findings
Gower sign due to proximal muscle weakness in the lower limbs
Pseudohypertrophy of the calves caused by fatty infiltration and fibrosis
Waddling gait from hip girdle muscle weakness
Decreased deep tendon reflexes in affected muscles
Muscle atrophy in later stages with contractures
Diagnostic Workup
Diagnostic Criteria
Diagnosis of Duchenne Muscular Dystrophy is established by a combination of clinical features such as early-onset proximal muscle weakness and calf pseudohypertrophy, along with markedly elevated serum creatine kinase (CK) levels. Confirmation requires genetic testing demonstrating a pathogenic mutation in the DMD gene or muscle biopsy showing absence or severe reduction of dystrophin protein by immunohistochemistry or Western blot. Family history and carrier testing may support diagnosis. Electromyography and cardiac evaluation are adjunctive but not diagnostic.
Pathophysiology
Key Mechanisms
Frameshift or nonsense mutations in the DMD gene lead to absence of dystrophin, a critical cytoskeletal protein.
Loss of dystrophin causes sarcolemma instability and increased susceptibility to muscle fiber damage during contraction.
Repeated muscle injury triggers chronic inflammation and fibrosis, progressively replacing muscle with connective tissue.
Deficient dystrophin disrupts the dystrophin-glycoprotein complex, impairing muscle cell membrane integrity and signaling.
Elevated intracellular calcium influx due to membrane fragility activates proteases that degrade muscle proteins.
| Involvement | Details |
|---|---|
| Organs | Skeletal muscles are the primary organs affected, resulting in progressive weakness and loss of ambulation. |
Heart is involved due to dystrophin deficiency causing dilated cardiomyopathy and heart failure. | |
Lungs are affected secondarily by respiratory muscle weakness leading to hypoventilation and respiratory failure. | |
| Tissues | Skeletal muscle tissue undergoes progressive necrosis and replacement by fibrofatty tissue leading to weakness. |
Cardiac muscle tissue is affected by fibrosis and degeneration causing cardiomyopathy and arrhythmias. | |
Connective tissue increases in affected muscles due to fibrosis, contributing to contractures and stiffness. | |
| Cells | Skeletal muscle cells are the primary affected cells due to absence of functional dystrophin leading to muscle fiber degeneration. |
Cardiomyocytes undergo progressive damage causing dilated cardiomyopathy in Duchenne muscular dystrophy. | |
Satellite cells attempt muscle regeneration but become exhausted over time contributing to muscle wasting. | |
| Chemical Mediators | Creatine kinase is elevated in serum as a marker of muscle damage in Duchenne muscular dystrophy. |
Inflammatory cytokines such as TNF-alpha contribute to muscle inflammation and fibrosis. | |
Dystrophin protein deficiency caused by mutations in the DMD gene is the fundamental molecular defect. |
Treatments
Pharmacological Treatments
Corticosteroids (e.g., prednisone, deflazacort)
- Mechanism:
Reduce muscle inflammation and slow muscle degeneration by modulating immune response and stabilizing muscle cell membranes.
- Side effects:
Weight gain
Osteoporosis
Hypertension
Glucose intolerance
Growth suppression
- Clinical role:
First-line
Exon-skipping therapies (e.g., eteplirsen)
- Mechanism:
Promote skipping of mutated exons in the DMD gene to restore the dystrophin reading frame and produce functional dystrophin protein.
- Side effects:
Injection site reactions
Proteinuria
Elevated liver enzymes
- Clinical role:
Adjunctive
Cardiac medications (e.g., ACE inhibitors, beta-blockers)
- Mechanism:
Manage cardiomyopathy by reducing cardiac workload and preventing heart failure progression.
- Side effects:
Hypotension
Bradycardia
Renal impairment
- Clinical role:
Supportive
Non-pharmacological Treatments
Physical therapy to maintain muscle strength and prevent contractures.
Use of orthotic devices to support weakened muscles and improve mobility.
Respiratory support including non-invasive ventilation to manage respiratory insufficiency.
Cardiac monitoring and management to detect and treat cardiomyopathy early.
Nutritional support to maintain optimal body weight and prevent malnutrition.
Prevention
Pharmacological Prevention
Corticosteroids such as prednisone or deflazacort to slow muscle degeneration
ACE inhibitors or beta-blockers to delay cardiomyopathy progression
Exon-skipping therapies targeting specific DMD mutations to restore dystrophin
Supplemental vitamin D and calcium to prevent steroid-induced osteoporosis
Non-pharmacological Prevention
Regular physical therapy to maintain muscle strength and prevent contractures
Use of orthotic devices to support weakened limbs and improve mobility
Cardiac and respiratory monitoring for early detection of complications
Nutritional support to maintain healthy weight and muscle mass
Genetic counseling for affected families to inform reproductive decisions
Outcome & Complications
Complications
Respiratory failure from progressive muscle weakness
Dilated cardiomyopathy leading to heart failure
Contractures and joint deformities from muscle fibrosis
Obesity due to reduced mobility
Infections such as pneumonia due to impaired cough
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Duchenne Muscular Dystrophy (DMD) versus Becker Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) | Becker Muscular Dystrophy |
|---|---|
X-linked recessive inheritance with absent or nonfunctional dystrophin | X-linked recessive inheritance with partially functional dystrophin |
Onset usually before 5 years of age | Onset typically in adolescence or early adulthood |
Rapid progression with loss of ambulation by early teens | Slower progression with longer ambulation |
Absent dystrophin on muscle biopsy or Western blot | Reduced but present dystrophin on muscle biopsy or Western blot |
Duchenne Muscular Dystrophy (DMD) versus Spinal Muscular Atrophy (SMA)
Duchenne Muscular Dystrophy (DMD) | Spinal Muscular Atrophy (SMA) |
|---|---|
X-linked recessive inheritance | Autosomal recessive inheritance |
Primary muscle fiber degeneration due to dystrophin deficiency | Lower motor neuron degeneration causing muscle atrophy |
Markedly elevated creatine kinase levels | Normal creatine kinase levels |
Mutation or deletion in DMD gene | Deletion or mutation in SMN1 gene |
Duchenne Muscular Dystrophy (DMD) versus Congenital Myopathies
Duchenne Muscular Dystrophy (DMD) | Congenital Myopathies |
|---|---|
Onset in early childhood with progressive weakness | Present at birth or infancy with hypotonia |
Absence of dystrophin with muscle fiber necrosis and regeneration | Characteristic structural abnormalities on muscle biopsy (e.g., nemaline rods, central cores) |
Markedly elevated creatine kinase | Normal or mildly elevated creatine kinase |
Duchenne Muscular Dystrophy (DMD) versus Polymyositis
Duchenne Muscular Dystrophy (DMD) | Polymyositis |
|---|---|
Non-inflammatory muscle fiber degeneration | Autoimmune inflammatory infiltrates with CD8+ T cells |
Childhood onset, usually <5 years | Adult onset, often >20 years |
Elevated creatine kinase without autoantibodies | Elevated muscle enzymes with positive autoantibodies |
No response to immunosuppressive therapy | Improves with immunosuppressive therapy |
Duchenne Muscular Dystrophy (DMD) versus Myotonic Dystrophy
Duchenne Muscular Dystrophy (DMD) | Myotonic Dystrophy |
|---|---|
X-linked recessive inheritance | Autosomal dominant inheritance |
Proximal muscle weakness without myotonia | Myotonia and distal muscle weakness |
Onset in early childhood | Onset in adolescence or adulthood |
Deletion or mutation in DMD gene | CTG trinucleotide repeat expansion in DMPK gene |